To identify the most critical PRMT for CBP resistance in HNSCC, we used siRNA to knock down PRMT1–9 in FaDu cells and assessed their survival under varying CBP concentrations. This evidence concerns the gene PRMT1 and head and neck squamous cell carcinoma.